Efficacy and safety of neoadjuvant pyrotinib plus docetaxel/liposomal doxorubicin/cyclophosphamide for HER2-positive breast cancer

被引：0
|
作者：
Chunyu Tian
Minghui Wang
Hancheng Liu
Jianping Liu
Mengze Xu
Lihui Ma
机构：
[1] Affiliated Hospital of Chengde Medical University,Department of Breast Surgery
[2] Chengde Medical University,School of Nursing
来源：
Irish Journal of Medical Science (1971 -) | 2023年 / 192卷 / 3期
关键词：
HER2; breast cancer; Neoadjuvant therapy; Pathological response; Pyrotinib; TAC;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1041 / 1049
页数：8
相关论文
共 50 条
  • [21] Cardiac safety of neoadjuvant chemotherapy with epirubicin and cyclophosphamide followed by docetaxel/pertuzumab/ trastuzumab for HER2-positive breast cancer patients
    Douganiotis, George
    Grigoriadis, Savvas
    Kontovinis, Loukas
    Markopoulou, Efrosini
    Pouptsis, Athanasios
    Papazisis, Konstantinos
    JOURNAL OF BUON, 2021, 26 (03): : 714 - 719
  • [22] Intracranial Efficacy of Pyrotinib and Capecitabine Combination Therapy in HER2-Positive Breast Cancer with Brain Metastases
    Wang, Congcong
    Xiang, Jinyu
    Zhang, Qingyu
    Li, Jing
    Liu, Yanqing
    Liu, Jiannan
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2024, 18 : 909 - 917
  • [23] Short-term efficacy and safety of neoadjuvant pyrotinib plus taxanes for early HER2-positive breast cancer: a single-arm exploratory phase II trial
    Ye, Guolin
    Chen, Peixian
    Liu, Xiangwei
    He, Tiancheng
    Pivot, Xavier
    Pan, Ruilin
    Zhou, Dan
    Zhu, Lewei
    Zhang, Kun
    Li, Wei
    Yang, Shuqing
    Lin, Jiawei
    Cai, Gengxi
    Huang, Huiqi
    GLAND SURGERY, 2024, 13 (03) : 374 - 382
  • [24] Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer
    Echavarria, Isabel
    Granja, Monica
    Bueno, Coralia
    Lopez-Tarruella, Sara
    Peinado, Paloma
    Sotelo, Miguel
    Jerez, Yolanda
    Moreno, Fernando
    Torres, Gabriela
    Lobo, Miriam
    Marquez-Rodas, Ivan
    Del Monte-Millan, Maria
    Martin, Miguel
    Angel Garcia-Saenz, Jose
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 162 (01) : 181 - 189
  • [25] Clinical efficacy of pyrotinib combined with chemotherapy for neoadjuvant treatment in HER2-positive breast cancer: a single-center study
    Wei, Benkai
    Yan, Huanhuan
    Li, Fan
    Shen, Jun
    ANTI-CANCER DRUGS, 2025, 36 (04) : 347 - 354
  • [26] Efficacy, toxicity and prognostic factors of pyrotinib-involved neoadjuvant therapy in HER2-positive breast cancer: A retrospective study
    Wang, Hao
    Cao, Hailing
    Guo, Zhiyun
    ONCOLOGY LETTERS, 2023, 26 (01)
  • [27] Pyrotinib and Trastuzumab Plus Chemotherapy Serve as an Acceptable Neoadjuvant Regimen Exhibiting Good Efficacy and Tolerance in HER2-Positive Breast Cancer Patients
    Chen, Yibo
    Zhang, Tianyi
    Zhang, Rui
    Cao, Xuchen
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2024, 39 (06) : 435 - 440
  • [28] Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer
    Tiwari, Shruti R.
    Mishra, Prasun
    Raska, Paola
    Calhoun, Benjamin
    Abraham, Jame
    Moore, Halle
    Budd, G. Thomas
    Fanning, Alicia
    Valente, Stephanie
    Stewart, Robyn
    Grobmyer, Stephen R.
    Montero, Alberto J.
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 158 (01) : 189 - 193
  • [29] Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer
    Shruti R. Tiwari
    Prasun Mishra
    Paola Raska
    Benjamin Calhoun
    Jame Abraham
    Halle Moore
    G. Thomas Budd
    Alicia Fanning
    Stephanie Valente
    Robyn Stewart
    Stephen R. Grobmyer
    Alberto J. Montero
    Breast Cancer Research and Treatment, 2016, 158 : 189 - 193
  • [30] The efficacy and safety of pyrotinib in treating HER2-positive breast cancer patients with brain metastasis: A multicenter study
    Gao, Min
    Fu, Chao
    Li, Shanshan
    Chen, Fang
    Yang, Yongteng
    Wang, Chunjian
    Qin, Jie
    Liu, Shuaishuai
    Zhang, Ranran
    Wang, Changyuan
    Zong, Jinbao
    Meng, Liping
    Meng, Xiangjiao
    CANCER MEDICINE, 2022, 11 (03): : 735 - 742
12345